Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Over $1.5 Million Raised For Covid-19 Vaccine Corporation Limited In Less Than An Hour

At 9am this morning, New Zealand’s Covid-19 Vaccine Corporation Limited (CVC) launched their PledgeMe campaign to raise up to $3.5 million. In under an hour, the wholesale campaign met its $1.5 million target and $35,000 was raised in the $2 million equity crowdfunding campaign.

CVC is in the process of developing the world’s first biobead Covid-19 vaccine, taking a different approach to other vaccination development organisations. The vaccine works with biobeads which get coated in small amounts of the virus, a feat the CVC team wanted to achieve first before going out to the public.

Cofounder, Dr Robert Feldman, states that before they’d managed to develop the biobeads, everything they’d been doing was purely theoretical.

“Previously, we had every reason to believe that we could make the beads coated in part of the virus, but now we have done it.”

Earlier last month, CVC raised $3.3 million in a private investment round. The funds raised from its current equity crowdfunding campaign will be used for further development and testing of the vaccine.

“We have encountered huge support from many quarters. We successfully licensed the technology from Polybatics, we were graced with amazing financial support from a group of investors and received an early and hugely helpful Government grant.”

CVC scientists have been working alongside Scion scientists to develop the vaccine at their facility in Rotorua.

“We now have the material that we need to test for production methods, analysis and develop methods to confirm our vaccine is exactly what we say it is. We have what we need for testing, and if everything goes successfully, we have the ‘mother’ of the actual vaccine we will give to the public,” says Dr Feldman.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

PledgeMe CEO, Dr. Claire McGowan, says “We are very happy with the progress of the campaign so far and that everyday New Zealanders have the opportunity to be part of a potentially successful Covid-19 vaccine”. 
CVC’s equity crowdfunding campaign launched on 11/11/20 at 9am NZDT. They are seeking to raise up to $3.5 million through their PledgeMe campaign (equity crowdfunding and wholesale). Shares are $0.80 each with a minimum investment of $500. Their wholesale campaign is funded and they've raised $61,400 through their equity campaign.

You can find the campaign and information memorandum here: https://pledgeme.co.nz/investments/428
Wholesale: https://pledgeme.co.nz/investments/432

About Covid-19 Vaccine Corporation Limited
Covid-19 Vaccine Corporation Limited (CVC) was founded in May 2020 to develop the world’s first biobead vaccine. It is made up of some of New Zealand’s top vaccine experts.

About PledgeMe
PledgeMe provides a platform for Kiwis and Aussies to go to their crowds for funding and has raised over $53 million for over 1500 campaigns in the past eight years.

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.